US Pharma MarketingExclusive: RA Capital backs intranasal viral prophylactic with $34M and a plan for Phase 2b
NorthLinks Bio, backed by RA Capital with $34M, is advancing HEX17 — an intranasal broad-spectrum viral prophylactic from Pneumagen — into a global Phase 2b protection study. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR…
RA Capital Management is backing a startup that wants to design an intranasal prophylactic for respiratory viruses.
The company is called NorthLinks Bio and is led by CEO Fanny Cavalié, a partner at an RA ...
Source: Endpoints News